(Q45909685)

17 December 2017

meta-analysis

0 references

title

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. (English)

1 reference

17 December 2017

0 references

1 reference

hepatocellular carcinoma

1 reference

Hui Zhang

1

1 reference

17 December 2017

Chun Gao

2

1 reference

17 December 2017

Long Fang

3

1 reference

17 December 2017

Hong-Chuan Zhao

4

1 reference

17 December 2017

Shu-Kun Yao

5

1 reference

17 December 2017

publication date

9 November 2012

1 reference

17 December 2017

Scandinavian Journal of Gastroenterology

published in

1 reference

17 December 2017

volume

48

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

78-87

1 reference

17 December 2017

Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Primary liver cancer: worldwide incidence and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Excess risk of primary liver cancer in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and neoplasia: implications and indications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin therapy and clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and other biguanides in oncology: advancing the research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Doctors seek to prevent breast cancer recurrence by lowering insulin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Targeting AMPK in the treatment of malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Understanding the benefit of metformin use in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Fixed- versus random-effects models in meta-analysis: Model properties and an empirical comparison of differences in results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma: results of a european case - control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Diabetes, cancer, and metformin: connections of metabolism and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin: taking away the candy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Metformin: multi-faceted protection against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.719926

10.3109/00365521.2012.719926

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

23137049

1 reference

17 December 2017